翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03692 翰森制药

未开盘 09-21 16:08:36

35.560

+1.260

+3.67%

最高35.780	最低34.020	成交量1,189万
今开34.020	昨收34.300	日振幅5.13%
总市值2,156亿	流通市值2,156亿	总股本60.64亿
成交额4.21亿	换手率0.20%	流通股本60.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"翰森制药","latestPrice":35.56,"timestamp":1789978116006,"preClose":34.3,"halted":0,"volume":11894635,"delay":0,"changeRate":0.03673469387755117,"floatShares":6064000000,"shares":6064000000,"eps":1.0901194043901903,"marketStatus":"未开盘","change":1.26,"latestTime":"09-21 16:08:36","open":34.02,"high":35.78,"low":34.02,"amount":421397717,"amplitude":0.051312,"askPrice":35.68,"askSize":6000,"bidPrice":35.56,"bidSize":46000,"shortable":3,"etf":0,"ttmEps":1.2983943357130527,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":0,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":34.3,"dividendRate":0.013936,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":1.3315313567513711,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2669165646","title":"翰森自免新药 III 期成功，拟报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2669165646","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669165646?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:32","pubTimestamp":1789990320,"startTime":"0","endTime":"0","summary":"9 月 21 日，翰森制药宣布，其自研酪氨酸激酶 2选择性变构抑制剂 HS-10374，在治疗成人中重度斑块状银屑病关键 III 期临床试验中达到共同主要终点和多项次要终点。这是一项随机、双盲、安慰剂对照、多中心 III 期临床，旨在评估HS-10374 治疗成人中重度斑块状银屑病患者的有效性和安全性。该研究当前已入组 503 名受试者，随机分配接受HS-10374 和安慰剂治疗。新闻稿显示，翰森制药计划近期启动与药监局的沟通，推进HS-10374 的新药上市申请准备工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-21/doc-inisqvrx7688236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","03692","BK1583","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111488037","title":"异动解读｜翰森制药盘中上涨3.03%，自研TYK2抑制剂三期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1111488037","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111488037?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:41","pubTimestamp":1789954909,"startTime":"0","endTime":"0","summary":"9月21日，翰森制药盘中上涨3.03%，报35.38港元，成交额5459.09万港元。消息面上，公司公告其自主研发的酪氨酸激酶2选择性变构抑制剂HS-10374在成人中重度斑块状银屑病关键性III期临床试验中达到共同主要终点。试验亦达到多项次要终点：第16周时超过一半患者达到PASI 90应答，近三分之一达到PASI 100应答。公司计划近期与监管机构沟通，推进在中国的新药上市申请准备工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药异动上涨，自研新药三期临床达标","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669133796","title":"翰森制药(03692.HK)：HS-10374治疗中重度斑块状银屑病III期临床研究达到共同主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2669133796","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669133796?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:36","pubTimestamp":1789951005,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03692","BK1583","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179373346","title":"翰森制药（03692.HK）自研TYK2抑制剂HS-10374三期试验达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1179373346","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179373346?lang=zh_cn&edition=full","pubTime":"2026-09-21 07:11","pubTimestamp":1789945861,"startTime":"0","endTime":"0","summary":"2026年9月21日，翰森制药集团有限公司公告，其自主研发的酪氨酸激酶2选择性变构抑制剂HS-10374在成人中重度斑块状银屑病关键性III期临床试验中达到共同主要终点。试验亦达到多项次要终点：第16周时，接受HS-10374治疗的患者中超过一半达到PASI 90应答，近1/3达到PASI 100应答。基于上述结果，翰森制药计划近期与相关监管机构沟通，推进在中国的新药上市申请准备工作，并拟在即将召开的皮肤学术会议上公布研究数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669138189","title":"翰森制药：HS-10374治疗中重度斑块状银屑病III期临床研究达共同主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2669138189","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669138189?lang=zh_cn&edition=full","pubTime":"2026-09-21 07:10","pubTimestamp":1789945800,"startTime":"0","endTime":"0","summary":"翰森制药：HS-10374治疗中重度斑块状银屑病III期临床研究达共同主要终点","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213879514636.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213879514636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188319038","title":"翰森制药（03692）自主开发1类新药HS-20197获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1188319038","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188319038?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:10","pubTimestamp":1789549841,"startTime":"0","endTime":"0","summary":"翰森制药集团有限公司（03692）9月16日公告称，其自主研发的1类新药注射用HS-20197已于2026年9月11日获得国家药品监督管理局签发的药物临床试验批准通知书，拟用于开展“晚期实体瘤”临床试验。公司董事会由主席兼执行董事钟慧娟女士授权发布本次自愿公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667260972","title":"翰森制药：注射用HS-20197获批临床 针对晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2667260972","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667260972?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:10","pubTimestamp":1789549800,"startTime":"0","endTime":"0","summary":"9月16日，翰森制药（03692）发布公告，公司自主研发的1类新药注射用HS-20197获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟用于开展“晚期实体瘤”的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163876108422.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163876108422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1589","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667472609","title":"翰森制药(03692.HK)：注射用HS-20197获国家药品监督管理局签发的药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667472609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667472609?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:05","pubTimestamp":1789549558,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","03692","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619853","title":"高盛：维持翰森制药(03692.HK)“买入“评级 12个月目标价52.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667619853?lang=zh_cn&edition=full","pubTime":"2026-09-15 13:42","pubTimestamp":1789450931,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667618675","title":"瑞银：翰森制药(03692.HK)Ris-Rez治疗复发小细胞肺癌研究结果令人鼓舞 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2667618675","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667618675?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:28","pubTimestamp":1789439329,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1583","BK1191","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655868","title":"【券商聚焦】华创证券维持翰森制药（03692）推荐评级 指创新药驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655868","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667655868?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:01","pubTimestamp":1789369287,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，翰森制药 2026年上半年实现总营业收入83.04亿元人民币，创新药收入约70.92亿元，占总收入比例约85.4%创历史新高；净利润42.58亿元。研发管线方面，公司创新药临床试验超70项，候选创新药超40个。华创证券指，公司创新药收入驱动业绩稳健增长，BD出海持续推进，在研管线储备丰富，看好聚焦创新和国际化的战略布局。预计2026-2028年营收分别为165.12/185.22/209.34亿元人民币，同比增长9.9%/12.2%/13.0%；归母净利润为61.10/67.78/75.09亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","KCE","03692","161027","159992","LNGR","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653378","title":"小摩：翰森制药(03692)靶向B7-H3 ADC产品治疗肺癌数据正面 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653378","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667653378?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:28","pubTimestamp":1789367309,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，翰森制药(03692)研发的靶向B7-H3抗体偶联药物(ADC)Ris-Rez日前公布最新研究数据，在治疗二线复发小细胞肺癌(2L SCLC)方面总生存期(OS)结果正面，与由宜联生物自主研发的靶向B7-H3 ADC产品Tam-Peli疗效相若，其中Ris-Rez中位数OS明显较长，而Tam-Peli则安全性可能较佳。该行维持翰森制药“增持”评级，目标价50港元，预测其创新药销售及授权收入将推动2020至2030年收入及盈利年均复合增长率分别达12%及15%，未来潜在催化剂包括商业化药物销售、后期资产关键数据读出及额外对外授权交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"小摩：翰森制药(03692)靶向B7-H3 ADC产品治疗肺癌数据正面 维持“增持”评级","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667630269","title":"港股异动 | 翰森制药(03692)涨近4% 瑞康立伏妥塔单抗的中位OS达到18.5个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667630269","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667630269?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:58","pubTimestamp":1789365528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨近4%，截至发稿，涨3.73%，报33.94港元，成交额2.05亿港元。消息面上，9月13日，翰森制药在2026世界肺癌大会首场主席论坛上，以最新突破性摘要形式口头报告自研B7-H3靶向ADC——瑞康立伏妥塔单抗的III期ARTEMIS-008研究期中结果。这次公布的数据，瑞康立伏妥塔单抗刷新了小细胞肺癌二线治疗最长总生存期纪录。具体看，瑞康立伏妥塔单抗的中位OS达到18.5个月，而托泊替康的中位OS是10.3个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","03692","KCAI","BK4588","BK1589","BK1191","BK1583","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161564678","title":"异动解读｜翰森制药盘中上涨3.12%，B7-H3 ADC在世界肺癌大会披露重磅III期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161564678","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161564678?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:35","pubTimestamp":1789353344,"startTime":"0","endTime":"0","summary":"消息面上，9月13日，翰森制药自主研发的B7-H3靶向ADC瑞康立伏妥塔单抗在世界肺癌大会首场主席论坛上以最新突破性摘要形式作口头报告，公布III期ARTEMIS-008研究期中分析结果：瑞康立伏妥塔单抗组中位总生存期达18.5个月，较标准治疗托泊替康组的10.3个月近乎翻倍，死亡风险降低54%，刷新全球小细胞肺癌二线治疗最长OS纪录。该研究为全球首个在随机对照III期中证实B7-H3靶向ADC带来OS获益的阳性研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药盘中上涨，B7-H3 ADC数据刷新纪录","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122596875","title":"翰森制药（03692）：注射用瑞康立伏妥塔单抗纳入NMPA优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1122596875","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122596875?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:43","pubTimestamp":1789116186,"startTime":"0","endTime":"0","summary":"2026年9月11日，翰森制药集团有限公司（03692）公告称，其注射用瑞康立伏妥塔单抗（HS-20093）已于2026年8月21日被国家药品监督管理局（NMPA）纳入优先审评审批程序。\n公司表示，此次纳入基于关键性III期临床试验ARTEMIS-008的积极结果，适应症为经含铂治疗失败的小细胞肺癌。\n公告并指出，这是公司主动披露的信息。截至公告日，董事会成员包括：主席兼执行董事钟慧娟女士，执行董事孙远女士、吕爱锋博士，以及独立非执行董事林国强先生、陈尚伟先生、杨东涛女士和严嘉先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156959565","title":"翰森制药注射用利斯维他妥珠雷泽替康纳入NMPA优先审评，针对小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1156959565","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156959565?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:35","pubTimestamp":1789115732,"startTime":"0","endTime":"0","summary":"翰森制药传来重磅消息——其研发的注射用利斯维他妥珠雷泽替康，已正式被国家药品监督管理局（NMPA）纳入优先审评程序，适应症指向小细胞肺癌。\n这一进展，无疑为饱受肺癌困扰的患者群体注入一剂强心针。优先审评通道的开启，意味着该药物有望加速上市，更快抵达临床前线。\n小细胞肺癌，素以恶性程度高、进展迅猛著称，治疗手段长期受限。而此次翰森制药的候选药物获得监管层面的“绿灯”，不仅凸显了其临床价值，也折射出企业在肿瘤领域的深耕布局。\n对于资本市场而言，这则动态值得密切关注。审评节奏的加快，或将重塑市场预期，为相关管线估值带来新的变量。\n眼下，一切尚待最终审批结果，但迈出这一步，已然意义非凡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","03692","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554787","title":"翰森制药(03692)：注射用瑞康立伏妥塔单抗(HS-20093)治疗小细胞肺癌纳入国家药品监督管理局优先审评审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554787?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:33","pubTimestamp":1789115584,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2026年8月21日，基于注射用瑞康立伏妥塔单抗 (HS-20093)(该产品)关键性III期试验ARTEMIS-008的积极结果，该产品用于经含铂治疗失败的小细胞肺癌适应症纳入中国国家药品监督管理局(NMPA)优先审评审批程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：注射用瑞康立伏妥塔单抗(HS-20093)治疗小细胞肺癌纳入国家药品监督管理局优先审评审批程序","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1191","BK1583","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137930257","title":"异动解读｜翰森制药盘中下跌3.06%，超预期中报大涨后连续回调延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1137930257","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137930257?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:51","pubTimestamp":1789091513,"startTime":"0","endTime":"0","summary":"9月11日，翰森制药盘中下跌3.06%，报32.36港元/股，成交额7576.04万港元。公司自8月27日因超预期中报大涨16.01%后已连续多日回调。消息面上，制药板块整体持续承压，石药集团跌2.0%、中国生物制药跌3.28%、恒瑞医药跌1.14%，个股普遍走弱。尽管公司上半年归母净利42.58亿元同比增长35.8%，创新药收入占比升至85.4%创历史新高，高盛、摩根大通等大行目标价上调至43.7至52.7港元区间，但板块弱势叠加前期卖空比例较高，获利回吐压力仍在释放。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药连续回调，创新药占比创新高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137387950","title":"异动解读｜翰森制药盘中下跌3.22%，制药板块整体承压延续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1137387950","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137387950?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:58","pubTimestamp":1789005504,"startTime":"0","endTime":"0","summary":"9月10日，翰森制药盘中下跌3.22%，报33.64港元/股，成交额1.11亿港元。翰森制药8月27日因超预期中报大涨16.01%后已连续回调。公司上半年收入83.04亿元，同比增长11.71%，归母净利42.58亿元，同比增长35.82%，创新药收入占比达85.4%创历史新高。尽管高盛、摩根大通等多家大行将目标价上调至43.7至52.7港元区间，但板块整体弱势叠加前期卖空比例较高，股价仍延续调整态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"翰森制药盘中下跌，制药板块整体承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","HK0000165453.HKD","01530","02096","01177","BK1515","BK1589","IE00BZ08YR35.GBP","BK1161","BK1574","BK1583","BK1521","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01477","03692","BK1593","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":0.075},{"period":"3month","weight":0.209},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.0293},{"period":"ytd","weight":-0.0081}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0372},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":-0.0229}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰森制药集团有限公司是一家主要从事一系列药品的研发、生产及销售的投资控股公司。该公司的创新药产品包括阿美乐、豪森昕福、迈灵达、孚来美、恒沐、昕越、圣罗莱等产品。该公司的创新药产品主要应用于抗肿瘤、抗感染、中枢神经系统（CNS）疾病、代谢及其他治疗领域。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.002557},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.012842},{"month":3,"riseRate":0.428571,"avgChangeRate":0.023369},{"month":4,"riseRate":0.571429,"avgChangeRate":0.033966},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.005203},{"month":6,"riseRate":0.571429,"avgChangeRate":0.039397},{"month":7,"riseRate":0.625,"avgChangeRate":0.011389},{"month":8,"riseRate":0.75,"avgChangeRate":0.028865},{"month":9,"riseRate":0.625,"avgChangeRate":-0.028116},{"month":10,"riseRate":0.142857,"avgChangeRate":0.0016},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063448},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016866}],"exchange":"SEHK","name":"翰森制药","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰森制药,03692,翰森制药股票,翰森制药股票老虎,翰森制药股票老虎国际,翰森制药行情,翰森制药股票行情,翰森制药股价,翰森制药股市,翰森制药股票价格,翰森制药股票交易,翰森制药股票购买,翰森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰森制药(03692)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰森制药(03692)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}